Interesting. I think an increase in revenue by 100% could set the company up for even larger growth. And as time goes and STI kits become available for sale across europe another 100% increase and so on. At the moment in gss infancy sales won't exactly equalize the costs of the company outgoings. However it won't take much to increase sales with new products such as the superbug kits and STI kits. Europe Australia and usa are large markets. In this field margins can increase significantly especially in the European and United states landscape.
My philosophy is that gss is a NAN in its infancy but has potential to capture a larger market with its varying diagnostic tests.
Also last year GSS did move to larger building for production scale up if I'm not mistaken ?
Ann: TGA registration for superbug detection kits, page-12
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.0¢ |
Change
-0.030(4.41%) |
Mkt cap ! $155.4M | |||
| Open | High | Low | Value | Volume |
| 66.0¢ | 66.0¢ | 65.0¢ | $26.35K | 39.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22897 | 65.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.0¢ | 56260 | 1 |
View Market Depth
| Last trade - 11.58am 04/12/2024 (20 minute delay) ? |
| GSS (ASX) Chart |
